CN109381488A - The topical agent and preparation method of epileptics - Google Patents
The topical agent and preparation method of epileptics Download PDFInfo
- Publication number
- CN109381488A CN109381488A CN201811576012.3A CN201811576012A CN109381488A CN 109381488 A CN109381488 A CN 109381488A CN 201811576012 A CN201811576012 A CN 201811576012A CN 109381488 A CN109381488 A CN 109381488A
- Authority
- CN
- China
- Prior art keywords
- epileptics
- parts
- topical agent
- bone
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001037 epileptic effect Effects 0.000 title claims abstract description 46
- 239000003860 topical agent Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 241000282994 Cervidae Species 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 13
- 239000002245 particle Substances 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 229910052779 Neodymium Inorganic materials 0.000 claims abstract description 9
- 230000005294 ferromagnetic effect Effects 0.000 claims abstract description 9
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 claims abstract description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 8
- 241001494479 Pecora Species 0.000 claims abstract description 8
- 229920001353 Dextrin Polymers 0.000 claims abstract description 7
- 239000004375 Dextrin Substances 0.000 claims abstract description 7
- 235000019425 dextrin Nutrition 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 7
- 206010010904 Convulsion Diseases 0.000 abstract description 3
- 206010015037 epilepsy Diseases 0.000 abstract description 3
- 208000028329 epileptic seizure Diseases 0.000 abstract description 3
- 238000007689 inspection Methods 0.000 abstract description 2
- 238000005057 refrigeration Methods 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000000803 paradoxical effect Effects 0.000 description 4
- 229940126701 oral medication Drugs 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- PXAWCNYZAWMWIC-UHFFFAOYSA-N [Fe].[Nd] Chemical compound [Fe].[Nd] PXAWCNYZAWMWIC-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Denomination of invention: the topical agent and preparation method fields of epileptics: the present invention relates to a kind of drug technique backgrounds for treating epileptics: there are many method drug for the treatment of epileptics at present but there is no treatment epileptic seizure up to now and improve the specific drug that patient increases physical efficiency.Summary of the invention: 20 parts of loadstone powder, ferromagnetic iron powder 10-30 parts of neodymium, 20-40 parts of sheep bone, 6-10 parts of keel, 10-20 parts of deer bone, 10-15 parts of river deer bone, 20 parts of bear bone.The preparation step of present invention treatment epileptics topical agent: it is dried and is smashed (except two of them powder after the raw material of the topical agent of epileptics is weighed up by weight ratio, above-mentioned raw materials are crushed to the particle of 800 mesh or more by pulverizer, appropriate dextrin and loadstone powder and the ferromagnetic iron powder of neodymium are added in feed particles, then paste is stirred into, epileptics topical agent after refrigeration is after test package, epileptics topical agent finished product, with the application method of epileptics topical agent of the present invention: the head stove that discharges on inspection is smeared, it cannot be interrupted, never recur.
Description
Technical field
Fields: the present invention relates to a kind of drugs for treating epileptics, especially a kind of for inhibiting epileptic seizure
Drug.
Background technique
Background technique: epileptics is common chronic disease, brings very big pain to patient, treats the method for epileptics at present
There are many drug, but there is no treatment epileptic seizure up to now and improve the specific drug that patient increases physical efficiency.Especially at present still
Without the externally applied drug for being directed to epileptics.Oral medicine has very big side effect to patient body, and there are many deficiencies, and effect is unobvious, and
And sb.'s illness took a turn for the worse for acceleration.
Summary of the invention
Summary of the invention: the purpose of the present invention is for epileptics drug therapy and oral drugs to patient outcomes not
Good shortcoming provides a kind of drug of external medication epileptics, and no longer recurrence significant in efficacy is safe and reliable, tolerance
It is good, without side-effects, the topical agent and preparation method of epileptics.
Technical solution used in the present invention is completed in the following way:
The raw material of the topical agent of epileptics includes loadstone powder, the ferromagnetic iron powder of neodymium, sheep bone, keel, deer bone, river deer bone, bear bone.
The weight proportion of raw material is 20 parts of loadstone powder, the ferromagnetic iron powder 10- of neodymium in the topical agent of above-mentioned epileptics
30 parts, 20-40 parts of sheep bone, 6-10 parts of keel, 10-20 parts of deer bone, 10-15 parts of river deer bone, 20 parts of bear bone.
The preparation step of the topical agent of above-mentioned epileptics is:
(1) it is dried, smashed (except two of them powder) after weighing up the raw material of the topical agent of epileptics by weight ratio.
(2) above-mentioned raw materials are crushed to the particle of 800 mesh or more by pulverizer.
(3) appropriate dextrin and loadstone powder and neodymium iron powder is added in the feed particles more than above-mentioned 800 mesh.Then
Paste is stirred into, wherein the weight proportion of epileptics topical agent feed particles and dextrin are as follows: epileptics topical agent raw material is micro-
100 parts 10-20 parts of dextrin of grain.
(4) epileptics topical agent is subjected to chilling treatment.
(5) refrigerate after epileptics topical agent through examining, after packaging, epileptics topical agent finished product.
With the application method of epileptics topical agent of the present invention: head stove area of discharging on inspection is smeared, and cannot be interrupted,
As long as accomplishing never to recur.
The present invention is understanding and principle of reatment based on externally applied drug treatment epileptics, referring to externally applied drug the study found that selection
Animal skeleton containing various effective components, forms by scientific practice, and externally applied drug generates a kind of unique electricity by magnet powder
Magnetic field impulse can quickly get through blood-brain barrier after being used as, and treatment targeting is made to schedule paradoxical discharge stove area, this addresses the problem
Oral drug therapy can not go directly the problem in paradoxical discharge stove area.Patient episode's number is reduced, patient's physical efficiency is restored, improves patient
Quality of life will play the role of key.
It is found through clinical comparison: after treating a course for the treatment of using externally applied drug of the invention, (using oral medicine with control group
Object) one course for the treatment of of treatment compares, and use externally applied drug of the invention to treat epileptics total effective rate as 98%.Oral medicine in control group
It is 2% that object, which treats total effective rate, and the total effective rate of externally applied drug treatment epileptics is compared, and is had the following characteristics that
1, it is raw material that the present invention, which selects loadstone and animal skeleton, and use is safe.It has no toxic side effect.
2, the present invention, which has, quickly gets through blood-brain barrier, so that treatment targeting is positioned at paradoxical discharge focal zone, solves medicine
Object treats the problem in the paradoxical discharge area that can not go directly, and curative effect is persistently prepared simple, safe and reliable.
Specific embodiment:
Invention is made below by embodiment and further being illustrated, but the present invention is not restricted to these example.
Embodiment 1
The topical agent of epileptics, it is made by loadstone and animal skeleton in following weight proportion.It is wherein natural
Magnet powder 20 divides, and ferromagnetic iron powder 10-30 parts of neodymium, 20-40 parts of sheep bone, 6-10 parts of keel, 10-20 parts of deer bone, 10-15 parts of river deer bone,
10-20 parts of bear bone.
Feature epileptics externally applied drug preparation step is: the raw material of above-mentioned treatment epileptics externally applied drug is dry through 40-60 degree
After 4-6 hours, it is crushed to the particle of 800 mesh or more by micronizer, then presses feed particles weight in feed particles again
5-10% be added dextrin stir into paste refrigeration.After test package epileptics externally applied drug finished product.
Embodiment 2
Epileptics topical agent, it is made by loadstone and animal skeleton in following weight proportion, wherein natural magnetic
15-30 parts of mountain flour, ferromagnetic mountain flour 10-20 parts of neodymium, 10-30 parts of sheep bone, 10-15 parts of keel, 15 parts of deer bone, 20 parts of river deer bone, bear bone
30 parts.
Epileptics topical agent preparation step is identical as implementing 1.
Embodiment 3
Epileptics topical agent, it is made by following weight proportion loadstone animal skeleton, wherein loadstone powder
10-20 parts, ferromagnetic iron powder 10-15 parts of neodymium, 20 parts of sheep bone, 15 parts of keel, 20 parts of deer bone, 10 parts of river deer bone, 10-25 parts of bear bone.
The preparation step of epileptics topical agent is same as Example 1.
Reference examples
To examine the present invention to the therapeutic effect of epileptic, following clinical test, clinical trial report are carried out to the present invention
It accuses as follows:
1, case selection
Selection meets case 15 of epileptics weight and attack times diagnostic criteria, and patient is randomly divided into two groups, treatment group 8
Example, wherein male 5 Genus Homo severe patients breaking-out in average 15 days is primary, 7 Genus Homo moderate patient of female breaking-out in average 30 days is primary.Age
It is 15-53 years old, average age 34 years old, the course of disease 2-10 months, 7 months average, control group 7, wherein male 4 people example, belongs to moderate trouble
It breaks out after person is 30 days average primary, the breaking-out in average 50 days of 3 category patients with mild of female is primary.Age at 20-40 years old, average age 30
In year, the course of disease 1-5 months, 3 months average, two groups of qualifications were almost the same, and there was no significant difference, are comparable.
2, treatment group patient smears month course for the treatment of of the invention, and control group uses oral drugs.
3, judgment criteria
Effective: breaking-out in severe patient 15 days is primary, and the state of an illness of not reaccessing after medication is controlled, and falls ill within moderate patient average 30 days
Not recurrence after medication.
It is invalid: to there are two patients to refuse medication, in vain.
4, result
With patient's effective percentage 98% of the invention, invalid 2%.
Effective percentage 2% in control group.
Treatment group's effective percentage is apparently higher than control group.
Claims (6)
1. the external application preparation and preparation method of epileptics.
2. a kind of epileptics topical agent, it is characterised in that its raw material is by loadstone powder, the ferromagnetic iron powder of neodymium, sheep bone, keel, deer
Bone, river deer bone, bear bone composition.
3. topical agent raw material proportioning are as follows: 20 parts of loadstone powder, ferromagnetic iron powder 10-30 parts of neodymium, 20-40 parts of sheep bone, keel 6-
10 parts, 10-20 parts of deer bone, 10-15 parts of river deer bone, 20 parts of bear bone.
4. epileptics topical agent according to claim 1, it is characterised in that epileptics topical agent has 800 mesh of particle or more
Externally applied drug feed particles composition.
5. the raw material of epileptics externally applied drug is controlled through temperature in 40-60 degree, drying time is 4-6 hours.
6. the weight proportion of epileptics topical agent feed particles and dextrin is 100 parts of feed particles, 10-20 parts of dextrin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811576012.3A CN109381488A (en) | 2018-12-22 | 2018-12-22 | The topical agent and preparation method of epileptics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811576012.3A CN109381488A (en) | 2018-12-22 | 2018-12-22 | The topical agent and preparation method of epileptics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109381488A true CN109381488A (en) | 2019-02-26 |
Family
ID=65430703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811576012.3A Pending CN109381488A (en) | 2018-12-22 | 2018-12-22 | The topical agent and preparation method of epileptics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109381488A (en) |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1303693A (en) * | 2000-01-10 | 2001-07-18 | 李世林 | Medicine for curing epilepsy by adopting head osmotic therapy |
| CN1720985A (en) * | 2005-07-05 | 2006-01-18 | 孙振华 | Erythromelalgia treating medicine |
| CN1927333A (en) * | 2006-08-30 | 2007-03-14 | 王家辉 | traditional Chinese medicine applied externally for treating epilepsy |
| CN101816771A (en) * | 2010-06-02 | 2010-09-01 | 泰一和浦（北京）中医药研究院有限公司 | Chinese medicinal composition for treating epilepsy disease and preparation method thereof |
| US20120009245A1 (en) * | 2006-04-25 | 2012-01-12 | Bankiewicz Krystof S | Administration of Growth Factors for the Treatment of CNS Disorders |
| CN103239262A (en) * | 2013-04-28 | 2013-08-14 | 曹莹莹 | Combined expansion head peg for intrusive suppression of epileptic attack |
| CN103431423A (en) * | 2013-07-23 | 2013-12-11 | 广州市全能鲜骨粉生物食品有限公司 | Fresh bone-meat powder, and preparation method and edible method thereof |
| CN103861213A (en) * | 2013-09-13 | 2014-06-18 | 高德和 | Multifunctional energy board |
| CN104208652A (en) * | 2014-10-09 | 2014-12-17 | 马俊安 | Traditional Chinese medicine for treating epilepsy and preparation method thereof |
| CN107812101A (en) * | 2017-11-15 | 2018-03-20 | 成都图瑞思舟科技有限公司 | One kind treats AED and preparation method |
| CN107929652A (en) * | 2017-10-26 | 2018-04-20 | 四川聚豪生物科技有限公司 | It is a kind of to be used to treat capsule medicine of epilepsy and preparation method thereof |
| CN108904741A (en) * | 2018-08-02 | 2018-11-30 | 甘南州合作市卡加曼藏药开发有限公司 | A kind of Tibetan medicinal preparation and preparation method thereof for treating apoplexy |
-
2018
- 2018-12-22 CN CN201811576012.3A patent/CN109381488A/en active Pending
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1303693A (en) * | 2000-01-10 | 2001-07-18 | 李世林 | Medicine for curing epilepsy by adopting head osmotic therapy |
| CN1720985A (en) * | 2005-07-05 | 2006-01-18 | 孙振华 | Erythromelalgia treating medicine |
| US20120009245A1 (en) * | 2006-04-25 | 2012-01-12 | Bankiewicz Krystof S | Administration of Growth Factors for the Treatment of CNS Disorders |
| CN1927333A (en) * | 2006-08-30 | 2007-03-14 | 王家辉 | traditional Chinese medicine applied externally for treating epilepsy |
| CN101816771A (en) * | 2010-06-02 | 2010-09-01 | 泰一和浦（北京）中医药研究院有限公司 | Chinese medicinal composition for treating epilepsy disease and preparation method thereof |
| CN103239262A (en) * | 2013-04-28 | 2013-08-14 | 曹莹莹 | Combined expansion head peg for intrusive suppression of epileptic attack |
| CN103431423A (en) * | 2013-07-23 | 2013-12-11 | 广州市全能鲜骨粉生物食品有限公司 | Fresh bone-meat powder, and preparation method and edible method thereof |
| CN103861213A (en) * | 2013-09-13 | 2014-06-18 | 高德和 | Multifunctional energy board |
| CN104208652A (en) * | 2014-10-09 | 2014-12-17 | 马俊安 | Traditional Chinese medicine for treating epilepsy and preparation method thereof |
| CN107929652A (en) * | 2017-10-26 | 2018-04-20 | 四川聚豪生物科技有限公司 | It is a kind of to be used to treat capsule medicine of epilepsy and preparation method thereof |
| CN107812101A (en) * | 2017-11-15 | 2018-03-20 | 成都图瑞思舟科技有限公司 | One kind treats AED and preparation method |
| CN108904741A (en) * | 2018-08-02 | 2018-11-30 | 甘南州合作市卡加曼藏药开发有限公司 | A kind of Tibetan medicinal preparation and preparation method thereof for treating apoplexy |
Non-Patent Citations (6)
| Title |
|---|
| CASTO RIVADULLA等: "Static magnetic fields reduce epileptiform activity in anesthetized rat and monkey", 《SCIENTIFIC REPORTS》 * |
| 张艳主编: "《全国中医药行业高等教育"十三五"规划教材配套用书中药学考点速查速记》", 30 November 2018, 中国医药科技出版社 * |
| 张葆青: "小儿癫痫中医文献与证治研究", 《中国优秀博硕士学位论文全文数据库（博士）医药卫生科技辑》 * |
| 杨仓良等主编: "《动物本草》", 31 January 2001, 中医古籍出版社 * |
| 王者悦主编: "《中国药膳大辞典》", 31 October 2017, 中国古籍出版社 * |
| 陈芳主编: "《名医别录彩色药图》", 28 February 2017, 贵州科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE502007010071C5 (en) | USE OF A MINERAL COMPOSITION AND, WHERE APPROPRIATE, ACETOGENIC AND / OR BUTYROGENIC BACTERIA TO AVOID OR REDUCE GAS FORMATION IN THE THICKNESS OF ANIMALS AND THEREFORE COMPLAINED ABDOMINAL | |
| AU2001255475B2 (en) | Method of reducing side effects of chemotherapy in cancer patients | |
| CN104257887A (en) | Composition for promoting lead excretion and application thereof | |
| AU2001255475A1 (en) | Method of reducing side effects of chemotherapy in cancer patients | |
| CN103461996A (en) | Toxin expelling, oxygenation and healthcare element capsule | |
| WO2012160549A2 (en) | Bioresonance therapy | |
| CN104351612A (en) | Sea cucumber, lucid ganoderma, glucan and selenium preparation and preparation method thereof | |
| CN109381488A (en) | The topical agent and preparation method of epileptics | |
| CN104473908A (en) | Cyclobenzaprine hydrochloride sustained release pellets and preparation method thereof | |
| EP2522350B1 (en) | Use of the active ingredient combination of a 1-diethylaminoethyl-3-chinoxalin-2-on derivative and an oxysterol for breaking resistance in the treatment of cancer and strengthening the immune system against cancer, bacterial and viral diseases, autoimmune diseases, increased stress and environmental influences | |
| CN109170302B (en) | Cat food and preparation method thereof | |
| CN102961515B (en) | Compound bee-glue composition for the treatment of swine erysipelas and preparation method thereof | |
| CN106924283A (en) | It is a kind of containing montmorillonite, the antidiarrheal pharmaceutical composition of medicinal carbon and preparation method and purposes | |
| Begg et al. | A comparison of efficacy and tolerance of the short acting sedatives midazolam and zopiclone | |
| Wang et al. | Application of novel nano-hydroxyapatite in proliferation and apoptosis of human osteosarcoma cells | |
| De Giorgi et al. | High-dose chemotherapy for adult-type ovarian granulosa cell tumors: a retrospective study of the European Society for Blood and Marrow Transplantation | |
| CN101222918A (en) | Methods and compositions for the treatment of pain | |
| CN108392482B (en) | β -methoxy acrylate compound and its application in preparing medicine for preventing and/or treating radiation injury | |
| Berenson et al. | A phase I/II trial evaluating the combination of arsenic trioxide, bortezomib and ascorbic acid for patients with relapsed or refractory multiple myeloma. | |
| CA2559634A1 (en) | Pharmaceutical preparations for the treatment of arthritis | |
| Tsyvunin et al. | Digoxin at sub-cardiotonic doses increases the anticonvulsive potential of classical anti-epileptic drugs on the experimental seizures induced by camphor | |
| CN110075232A (en) | A kind of Chinese medicine composition and its preparation method and application for treating animal diarrhea | |
| Allen | Calcium sensitivity and muscle disease. | |
| CN105832737B (en) | A kind of pharmaceutical composition and its application comprising vilazodone | |
| CN105616500A (en) | Pharmaceutical composition for treating cestodiasis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190226 |